TY - JOUR T1 - Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition JF - Anticancer Research JO - Anticancer Res SP - 301 LP - 306 VL - 38 IS - 1 AU - MORIKAZU MIYAMOTO AU - MASASHI TAKANO AU - TADASHI AOYAMA AU - HIROAKI SOYAMA AU - HIROKI ISHIBASHI AU - KENTO KATO AU - HIDEKI IWAHASHI AU - KAZUKI TAKASAKI AU - MIKA KUWAHARA AU - HIROKO MATUURA AU - TAKAHIRO SAKAMOTO AU - TOMOYUKI YOSHIKAWA AU - KENICHI FURUYA Y1 - 2018/01/01 UR - http://ar.iiarjournals.org/content/38/1/301.abstract N2 - Background/Aim: To investigate whether XIAP down-regulation and autophagy inhibition sensitize ovarian clear cell cancer cells to cisplatin. Materials and Methods: The ovarian clear cancer cell line KK was used for in vitro analysis. Hydroxychloroquine (HCQ) and phenoxodiol (PXD) or embelin were used as autophagy and XIAP inhibitors, respectively. Non-specific and XIAP-specific siRNAs were transfected using Lipofectamine. Cytotoxicity was assessed by MTT assays. Protein expression was confirmed by western blotting. Results: In KK, down-regulation of XIAP using specific siRNAs together with HCQ treatment enhanced the anti-tumor effect of cisplatin. Although embelin sensitized KK to cisplatin through XIAP down-regulation, it induced autophagy. However, PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition. Expression of Atg7, Atg12, and Beclin 1 was decreased after PXD treatment. Conclusion: PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition and could be a new candidate for ovarian clear cell carcinoma treatment. ER -